FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jul. 03, 2026

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):


	Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
July 3, 2026

Assets: Foreign currency hedging contracts	$	2,577	$	—	$	2,577	$	—
Liabilities: Foreign currency hedging contracts	1,452		—		1,452		—

Liabilities: Contingent consideration	7,000		—		—		7,000

December 31, 2025



Liabilities: Foreign currency hedging contracts	$	5,221	$	—	$	5,221	$	—
Liabilities: Contingent consideration	8,179		—		—		8,179

Information regarding outstanding foreign currency forward contracts as of July 3, 2026 is as follows (dollars in thousands):


Notional Amount		Maturity Date	$/Foreign Currency		Fair Value		Balance Sheet Location

$	31,383	Jul 2027	0.0522	MXN Peso	$	2,533	Prepaid expenses and other current assets
2,474		Jul 2027	0.2443	MYR Ringgit	20		Prepaid expenses and other current assets
4,201		Jul 2027	0.0247	UYU Peso	24		Prepaid expenses and other current assets

40,679		Jul 2027	1.1794	Euro	(957)		Accrued expenses and other current liabilities
19,589		Jul 2027	0.0567	MXN Peso	(129)		Accrued expenses and other current liabilities
2,555		Apr 2027	0.2591	MYR Ringgit	(126)		Accrued expenses and other current liabilities
8,695		Apr 2027	0.0255	UYU Peso	(209)		Accrued expenses and other current liabilities
3,752		Oct 2027	0.0558	MXN Peso	(31)		Other long-term liabilities

Information regarding outstanding foreign currency forward contracts as of December 31, 2025 is as follows (dollars in thousands):


Notional Amount		Maturity Date	$/Foreign Currency		Fair Value		Balance Sheet Location
$	15,906	Oct 2026	1.1610	Euro	$	266	Prepaid expenses and other current assets
7,649		Oct 2026	0.0244	UYU Peso	383		Prepaid expenses and other current assets
51,699		Dec 2026	0.0501	MXN Peso	4,491		Prepaid expenses and other current assets
2,959		Oct 2026	0.2401	MYR Ringgit	82		Prepaid expenses and other current assets
3,842		Apr 2027	0.0519	MXN Peso	76		Other long-term assets
8,923		Jul 2026	1.1898	Euro	(77)		Accrued expenses and other current liabilities

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)

The following tables present the effect of cash flow hedge derivative instruments on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended July 3, 2026 and June 27, 2025 (in thousands):


	Three Months Ended
	July 3, 2026				June 27, 2025
	Total		Amount of Gain (Loss) on Cash Flow Hedge Activity		Total		Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales	$	464,110	$	(181)	$	476,494	$	725
Cost of sales	351,168		1,878		347,342		277
Operating expenses	78,414		—		69,814		(1)



	Six Months Ended
	July 3, 2026				June 27, 2025
	Total		Amount of Gain (Loss) on Cash Flow Hedge Activity		Total		Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales	$	903,690	$	(1,356)	$	913,886	$	142
Cost of sales	681,153		2,420		664,416		(416)
Operating expenses	156,140		(92)		140,580		(18)

(13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)


	Unrealized Gain (Loss) Recognized in OCI				Realized Gain (Loss) Reclassified from AOCI
	Three Months Ended				Location in Statements of Operations and Comprehensive Income	Three Months Ended
	July 3, 2026		June 27, 2025			July 3, 2026		June 27, 2025

Foreign exchange contracts	$	(220)	$	2,938	Sales	$	(181)	$	725
Foreign exchange contracts	2,353		5,214		Cost of sales	1,878		277
Foreign exchange contracts	—		126		Operating expenses	—		(1)

	Six Months Ended					Six Months Ended
	July 3, 2026		June 27, 2025			July 3, 2026		June 27, 2025

Foreign exchange contracts	$	(104)	$	4,746	Sales	$	(1,356)	$	142
Foreign exchange contracts	5,172		7,633		Cost of sales	2,420		(416)
Foreign exchange contracts	—		299		Operating expenses	(92)		(18)

Schedule of Estimated Fair Values for Contingent Consideration

The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the three and six months ended July 3, 2026 and June 27, 2025 (in thousands):


	Three Months Ended				Six Months Ended
	July 3, 2026		June 27, 2025		July 3, 2026		June 27, 2025
Fair value measurement at beginning of period	$	8,179	$	3,445	$	8,179	$	904
Amount recorded for current year acquisitions	—		—		—		2,541
Fair value measurement adjustment	(1,179)		(309)		(1,179)		(309)


Fair value measurement at end of period	$	7,000	$	3,136	$	7,000	$	3,136

Schedule of Business Combination, Contingent Consideration

The following table provides information on unpaid contingent consideration as of July 3, 2026 (in thousands):


			As of July 3, 2026
			Maximum Remaining Payout (undiscounted)
Acquisition	Acquisition Date	RemainingMilestone Years	2026		2027		2028		2029		Total		Fair Value
Biocoat	12/04/25	2026	$	7,000	$	—	$	—	$	—	$	7,000	$	7,000
VSi	02/28/25	2026 - 2028	—		1,000		1,000		1,000		3,000		—


InNeuroCo	10/01/23	2026 - 2027	—		2,700		2,700		—		5,400		—

Schedule of Equity Method and Other Investments

Equity and other investments comprise the following (in thousands):


	July 3, 2026		December 31, 2025
Equity method investment	$	6,239	$	7,709
Non-marketable equity securities	180		180
Convertible debt instrument	13,722		—
Total equity and other investments	$	20,141	$	7,889

During the first quarter of 2026, the Company invested 12 million euro ($13.8 million) in a convertible debt instrument issued by a life sciences company that matures on December 31, 2035. The instrument has a stated interest of 4.55%, payable periodically during the term of the instrument. Depending on certain operational and financial targets, the Company may invest an additional 3 million euro under the same terms. The instrument is senior to all other indebtedness, and is secured by the assets of the investee. The Company considered guidance within ASC 815 and concluded the conversion option did not require bifurcation as an embedded derivative instrument.

The components of (Gain) loss on equity investments for each period were as follows (in thousands):


	Three Months Ended				Six Months Ended
	July 3, 2026		June 27, 2025		July 3, 2026		June 27, 2025
Equity method investment (gain) loss	$	(42)	$	8	$	1,426	$	(173)